Comparative Pharmacology
Head-to-head clinical analysis: SUCCINYLCHOLINE CHLORIDE versus SUCOSTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUCCINYLCHOLINE CHLORIDE versus SUCOSTRIN.
SUCCINYLCHOLINE CHLORIDE vs SUCOSTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depolarizing neuromuscular blocker that binds to nicotinic acetylcholine receptors at the motor endplate, causing initial depolarization followed by sustained membrane depolarization and desensitization, leading to muscle paralysis.
Succinylcholine is a depolarizing neuromuscular blocker that binds to and activates nicotinic acetylcholine receptors at the neuromuscular junction, causing initial muscle fasciculations followed by prolonged depolarization and receptor desensitization, resulting in neuromuscular blockade.
1-1.5 mg/kg IV bolus for intubation; 2.5-4 mg/kg IM if IV access unavailable.
IV: 0.3-1.1 mg/kg initially, then maintenance of 0.04-0.07 mg/kg as needed or continuous infusion of 2.5-4.3 mg/min.
None Documented
None Documented
The terminal elimination half-life of succinylcholine is approximately 2–4 minutes in patients with normal pseudocholinesterase activity. Clinically, this short half-life correlates with rapid offset of neuromuscular blockade. In patients with atypical or deficient pseudocholinesterase, half-life may be prolonged to 20–60 minutes or more.
Terminal elimination half-life is approximately 2-4 minutes for succinylcholine (rapid hydrolysis by plasma pseudocholinesterase). In patients with atypical pseudocholinesterase or deficiency, half-life may be prolonged to 20-60 minutes, leading to prolonged paralysis.
Succinylcholine is rapidly hydrolyzed by plasma pseudocholinesterase. Only 2-10% of the administered dose is excreted unchanged in the urine; the remainder is metabolized to succinylmonocholine and further to succinic acid and choline. Biliary/fecal elimination is negligible.
Primarily renal excretion of unchanged drug and metabolites (succinylmonocholine); minimal biliary/fecal elimination (<2%). Approximately 10-20% excreted unchanged in urine, with the remainder as succinylmonocholine.
Category C
Category C
Neuromuscular Blocker (Depolarizing)
Neuromuscular Blocker (Depolarizing)